Rewiring the Chronic Pain Experience: Single-Session Model of Pain Reprocessing Therapy (PRT) at The Ottawa Hospital
NCT07919626, Not applicable, Recruiting, Ottawa Hospital Research Institute
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Rewiring the Chronic Pain Experience: Single-Session Model of Pain Reprocessing Therapy (PRT) at The Ottawa Hospital | ClinicalTrials.gov |
| NCT number | NCT07919626 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Ottawa Hospital Research Institute | ClinicalTrials.gov |
| Conditions | Chronic Pain | ClinicalTrials.gov |
| Interventions | PRT (Pain Reprocessing Therapy) | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Clinical Effectiveness: Brief Pain Inventory (BPI) Pain Intensity and Pain Interference | Baseline, 1 week post-intervention, 1 month follow up. | Clinical effectiveness outcome measurement tools include Brief Pain Inventory (BPI): Participants will localize their pain through a drop down menu, in which they will select the applicable body part(s) where they experience pain. The BPI Pain Intensity and Pain Interference scales will then be administered. The pain intensity subscale includes 4 pain intensity ratings using an 11-point numerical rating scale (0-10) on current pain, average pain, worst pain during the last 7 days and least pain during the last 24 hours. The pain interference subscale includes 7 interference items that ask the patient to respond using an 11-point numerical rating scale (0-10). These items include the effect on general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life. | ClinicalTrials.gov |
| Primary | Interview | Interviews will be conducted within 6 months of participating in the PRT session. | A random selection of participants will be interviewed regarding their PRT experience. | ClinicalTrials.gov |
| Primary | Clinical Effectiveness: Pain Self-Efficacy Questionnaire (PSEQ-10) | Baseline, 1 week post-intervention, 1 month follow up. | Clinical effectiveness outcome measurement tools include Pain Self-Efficacy Questionnaire (PSEQ-10): The PSEQ-10 is a validated 10-item tool for assessing the patient's pain self-efficacy or belief in one's capability to perform activities even when undergoing pain. The 10 items ask the patient to rate their confidence in doing activities on a 7-point numerical rating scale (0-6), with higher scores indicating greater confidence. | ClinicalTrials.gov |
| Primary | Clinical Effectiveness: Patients' Global Impression of Change (PGI-C) Scale | 1 week post-intervention, 1 month follow up. | Clinical effectiveness outcome measurement tools include Patients' Global Impression of Change (PGI-C) Scale: The PGI-C is a validated single- item self-report measure used to assess a patient's perceived change in overall status following a treatment or intervention. Patients select one of 7 options to describe their experience, ranging from "very much worse" to "very much improved." The PGI-C is widely used in chronic pain research and has demonstrated sensitivity to clinically meaningful change across a range of pain populations. | ClinicalTrials.gov |
| Primary | Clinical Effectiveness: Positive and Negative Affect Scale (PANAS) | Day of Intervention, 1 week post-intervention, 1 month follow up. | Clinical effectiveness outcome measurement tools include Positive and Negative Affect Scale (PANAS) PANAS is a validated 20-item self-report measure assessing two distinct dimensions of mood: positive affect and negative affect. Participants rate the extent to which they have experienced each emotion using a 5-point Likert scale (1 = very slightly or not at all, 5 = extremely), with higher positive affect scores and lower negative affect scores reflecting better emotional well-being. The PANAS has demonstrated strong reliability and validity across clinical populations, including individuals with chronic pain. | ClinicalTrials.gov |
| Secondary | Feasibility of recruitment | Baseline | • Rates of participant eligibility and consenting will be tracked o The single session PRT model will be considered feasible if we can recruit our target sample size of 40 participants over a 6-month period. | ClinicalTrials.gov |
| Secondary | Rate of participant accrual/completion | Baseline, Day 7, and Day 30 | • Rates of participant accrual, screening, and 1-week and 1-month assessment completion will be tracked o The evaluation procedures will be considered feasible if we retain more than 80% of participants at 1-month follow-up. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)